Respiratory disease is a huge global issue, with asthma and chronic obstructive pulmonary disease (COPD) affecting hundreds of millions globally. COPD was reported by the WHO as the third-leading...
Pharmaceuticals

Apr 12, 2023 | Published by Broughton
Pharmaceuticals
Broughton has been featured in an article on ‘Making Inhaled Therapies Fit for the Future: Improving the Sustainability of Pressurised Metered Dose Inhalers’ for Innovations in Pharmaceutical Technology magazine.
The article investigates how pressured metered dose inhalers (pMDIs) have become the most popular treatment choice for patients suffering from common respiratory diseases such as asthma, despite pMDIs accounting for 3.9% of the NHS’s annual carbon emissions. Andrew looks at what options are available to improve the sustainability of the device in the future. You can read the full article here -
Ensure your business stays ahead of the competition by keeping up to date with the latest industry news. Sign-up for our newsletter to have the latest information and insights served directly to your inbox.
Respiratory disease is a huge global issue, with asthma and chronic obstructive pulmonary disease (COPD) affecting hundreds of millions globally. COPD was reported by the WHO as the third-leading...
On October 29, 2021, the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) updated its guidance for licensing electronic cigarettes and other inhaled nicotine-containing products as...
~ Key considerations for designing electronic cigarettes and other inhaled nicotine-containing products as medicines ~